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Association Between Genetic Variation in FOXO3 and
Reductions in Inflammation and Disease Activity in
Inflammatory Polyarthritis
Sebastien Viatte,1 James C. Lee,2 Bo Fu,3 Marion Espeli,4 Mark Lunt,1 Jack N. E. De Wolf,1
Lily Wheeler,1 John A. Reynolds,1 Madhura Castelino,1 Deborah P. M. Symmons,5
Paul A. Lyons,2 Anne Barton,5 and Kenneth G. C. Smith2
Objective. Genetic variation in FOXO3 (tagged by
rs12212067) has been associated with a milder course
of rheumatoid arthritis (RA) and shown to limit
monocyte-driven inflammation through a transforming
growth factor b1–dependent pathway. This genetic asso-
ciation, however, has not been consistently observed in
other RA cohorts. We sought to clarify the contribution
of FOXO3 to prognosis in RA by combining detailed
analysis of nonradiographic disease severity measures
with an in vivo model of arthritis.
Methods. Collagen-induced arthritis, the most
commonly used mouse model of RA, was used to assess
how Foxo3 contributes to arthritis severity. Using clin-
ical, serologic, and biochemical methods, the arthritis
that developed in mice carrying a loss-of-function
mutation in Foxo3 was compared with that which
occurred in littermate controls. The association of
rs12212067 with nonradiographic measures of RA
severity, including the C-reactive protein level, the
swollen joint count, the tender joint count, the Disease
Activity Score in 28 joints, and the Health Assessment
Questionnaire score, were modeled longitudinally in a
large prospective cohort of patients with early RA.
Results. Loss of Foxo3 function resulted in more
severe arthritis in vivo (both clinically and histologically)
and was associated with higher titers of anticollagen anti-
bodies and interleukin-6 in the blood. Similarly, rs12212067
(a single-nucleotide polymorphism that increases FOXO3
transcription) was associated with reduced inflammation,
both biochemically and clinically, and with lower RA ac-
tivity scores.
Conclusion. Consistent with its known role in
restraining inflammatory responses, FOXO3 limits
the severity of in vivo arthritis and, through genetic
variation that increases its transcription, is associated
with reduced inflammation and disease activity in RA
patients, effects that result in less radiographic
damage.
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Like most autoimmune and inflammatory condi-
tions, the course of rheumatoid arthritis (RA) is unpre-
dictable and is highly variable between patients. While
current guidelines advocate early and aggressive treat-
ment for all patients in order to avoid irreversible joint
damage and disability, this strategy will undoubtedly
result in the overtreatment of patients with mild disease
or those in whom the disease would have spontaneously
entered remission. Accordingly, such patients are cur-
rently exposed to the risks and side effects of unneces-
sary immunosuppression. To overcome this limitation, a
personalized management strategy would be necessary,
which in turn, would rely on having a reliable method
of predicting disease outcome. Currently, however, the
predictive value of clinical or serologic markers is insuf-
ficient to guide treatment decisions and, accordingly,
there is a clear and well-recognized need for predictive
biomarkers.
Genetics has been shown to play an important
role in the development of RA through a series of large
genome-wide association studies (GWAS) (1–3), but its
potential role in determining disease course following
diagnosis has been less rigorously studied, even though
radiographic outcome has been proposed to be partially
genetically determined (4). Indeed, while many studies have
reported genetic associations with outcome, virtually none
of these outside the HLA reach genome-wide significance,
nor have the associations always been replicated (5–9).
We previously demonstrated that a single-nucleotide
polymorphism (SNP) in FOXO3A (rs12212067; T.G)
was associated with prognosis in several tumor necrosis
factor (TNF)–driven diseases and that this variant led
to altered production of pro- and antiinflammatory
cytokines by monocytes through a transforming growth
factor b1 (TGFb1)–dependent pathway (10). In RA spe-
cifically, we showed that minor allele carriage at rs12212067,
which reduced the production of TNF, interleukin-6 (IL-6),
IL-1b, and IL-8 and increased the production of IL-10, was
associated with a milder disease course (i.e., less joint
damage over time) in large and well-phenotyped cohorts of
patients with early disease. Since that report, which also
demonstrated that rs12212067 was associated with outcome
in Crohn’s disease and malaria, several smaller studies have
attempted to replicate these associations. In Crohn’s disease
(11) and malaria (12), the reported associations were
independently replicated, although in RA, a meta-analysis
of 5 smaller cohorts from the US and Europe failed to
detect the same association signal (13). This situation is not
unusual and in fact is similar to what occurred in the early
era of GWAS when some of the first associations—many
of which have since been replicated several times—were
initially questioned by negative findings of follow-up studies
in small and consequently underpowered cohorts (14–16).
Here, we sought to better understand what contri-
bution FOXO3 might make to the clinical outcome of RA.
To do this, we first investigated whether a role of FOXO3
in altering arthritis severity was biologically plausible by
examining the contribution of FOXO3 to the severity of
immune-mediated arthritis in vivo. We then chose to
examine a broader range of arthritis severity markers in a
large cohort of patients with early RA and inflammatory
polyarthritis to determine whether other associations
might be present that would support (or indeed refute)
the association of rs12212067 with outcome in RA.
MATERIALS AND METHODS
Collagen-induced arthritis. To study the role of
FOXO3 in immune-mediated arthritis in vivo, we used the
collagen-induced arthritis mouse model, the most commonly
used animal model of RA, in which arthritis is induced by immu-
nization with emulsified type II collagen in Freund’s complete
adjuvant (50 ml of a 4 mg/ml preparation administered intrader-
mally). We compared the severity of the resulting arthritis in
C57BL/6 mice harboring a missense mutation in the highly con-
served forkhead DNA-binding domain that abrogates the func-
tion of Foxo3 (Foxo3aMommeR1/MommeR1 mice; hereinafter
referred to as Foxo3a–/– mice) (17), with the arthritis that devel-
oped in heterozygous (Foxo3a1/–) and wild-type (Foxo3a1/1)
littermates (all 8 weeks old). Arthritis severity was assessed using
a standard scoring system (18). Serum anticollagen antibodies
(Chondrex) and IL-6 and TNF levels (R&D Systems) were
assessed by enzyme-linked immunosorbent assay on day 14. All
experiments were performed according to the regulations of the
UK Home Office Scientific Procedures Act (1986).
Patient cohorts and genotyping. To further investi-
gate the relationship between rs12212067 (a noncoding SNP
within FOXO3) and disease severity in RA, we used the
Norfolk Arthritis Register (NOAR), a primary care–based
inception cohort of 4,293 patients with early inflammatory
polyarthritis who were monitored prospectively from disease
onset up to 20 years (19) (Supplementary Table 1, available on
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39760/abstract). Inflammatory polyar-
thritis patients who satisfied the American College of Rheuma-
tology 1987 criteria for RA (20), which were applied
cumulatively over the first 5 years of follow-up, were designated
as RA patients (n5 2,537) (see Supplementary Table 1).
Where data were available, we analyzed the association
of genotype at rs12212067 with a range of RA severity indices,
including radiographic measures (Larsen score [21], modified
Larsen score, and presence of erosions, defined as a cortical
break $2 mm), biologic measures (C-reactive protein [CRP]
level), patient-reported outcomes (Health Assessment Question-
naire [HAQ] score), and disease activity scores (swollen joint
count, tender joint count, and Disease Activity Score in 28 joints
[DAS28] calculated using the swollen joint count, tender joint
count, and CRP level). Genotyping of rs12212067 was performed
on a custom-designed genotyping chip (Illumina ImmunoChip)
or using Sequenom MassArray technology. Quality control
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procedures for the ImmunoChip data were as described in the
original report (2). Ethical approval for the NOAR study was
given by the Norwich Research Ethics Committee, and all
patients gave informed consent.
Statistical analysis. In order to maximize the power
for the study of outcome in RA and inflammatory polyarthri-
tis, we incorporated multiple records per patient over time and
considered all measures of disease outcome (or activity) as
longitudinal continuous variables. All analyses were adjusted
for intraindividual correlation, and a dominant model of asso-
ciation was used (in part due to the low frequency of minor
allele homozygotes). To provide a positive control, we used
the same method to analyze the shared epitope (SE), a
5–amino acid sequence motif in the HLA–DRb chain that
is known to be associated with a variety of measures of se-
vere RA. The presence or absence of the SE was determined
experimentally using the reverse dot-blot method, as
described previously (22). We used generalized linear latent
and mixed modeling for measures of radiographic outcome
(23), zero-inflated negative binomial regression for the CRP
level (24), and quantile (median) regression for the HAQ
score, swollen joint count, tender joint count, and DAS28.
See the Supplementary Methods (available on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.39760/ abstract) for further details.
Because the directions of effect of the SE and the
FOXO3A SNP are already known, 1-tailed P values are reported,
as in the original study (10). Adjustment for multiple testing and
treatment strategies was performed where indicated. Treatment
was integrated in the model as a time-dependent dummy variable
for the presence of treatment with any disease-modifying
antirheumatic drug at every follow-up visit. The proportion of the
variance of a specific trait explained by the FOXO3A SNP was
calculated as follows. The model was run with and without the
SNP. For each model, the correlation coefficient between the
observed and predicted values was calculated. The difference
between the squares of the correlation coefficients was used
to quantify the proportion of the variance explained by the SNP.
These analyses were performed using Stata version 11/13 soft-
ware (StataCorp).
In the collagen-induced arthritis experiments, compar-
ison of the arthritis score between the Foxo3–/–, Foxo31/–, and
Foxo31/1 mouse groups was performed using a two-way analysis
of variance, and comparison of biochemical or serologic parame-
ters between genotypes was performed using Wilcoxon’s matched
pairs signed rank test. One-tailed P values are presented in view
of the specific hypothesis being tested. These analyses were per-
formed using GraphPad Prism v6.04 software.
RESULTS
To investigate how altered FOXO3 function might
influence the course of autoimmune arthritis in vivo, we
first assessed the severity of collagen-induced arthritis in
mice carrying a missense mutation in the highly conserved
forkhead DNA-binding domain of Foxo3, which is known
to abrogate its function. We found that carriage of the
Foxo3-null allele was associated with more-severe arthri-
tis. This was apparent from both the significantly higher
arthritis scores (Figure 1A) and the joint histology
findings, which demonstrated increased synovial expan-
sion and cellularity and tissue edema (Figure 1B). In
addition to assessing the clinical severity of arthritis, we
also sought to compare the titers of anticollagen anti-
bodies that were formed, as this enables a more direct
evaluation of the immune response against type II colla-
gen. These antibodies are also known to target epitopes
within type II collagen that are shared by RA antibodies
(25). We demonstrated that higher levels of anticollagen
antibodies were present in mice with impaired or abro-
gated Foxo3 function (Figure 1C). On day 14, we also
assessed the production of IL-6 and TNF, proinflamma-
tory cytokines that are known to be important in the path-
ogenesis of collagen-induced arthritis, and observed a
nonsignificant trend toward higher IL-6 levels in Foxo3–/–
mice as compared to either the wild-type or heterozygous
littermates (P5 0.06) (Figure 1D). Serum TNF was not
detectable at this time point (data not shown).
Figure 1. Loss of Foxo3 activity and predisposition to more severe
arthritis in Foxo3–/–, Foxo31/–, and Foxo31/1 littermate mice with
collagen-induced arthritis. A, Arthritis scores in the 3 mouse groups.
Each limb was scored on a scale of 0–4 according to the method of
Brand et al (18), and the scores were summed. B, Light microscopy of
hematoxylin and eosin–stained sections of joints obtained on day 14
from Foxo31/1 and Foxo3–/–mice, demonstrating joint space narrowing
and synovial expansion. C, Serum anticollagen antibody titers on day
14. D, Serum levels of interleukin-6 (IL-6) on day 14. Results are rep-
resentative of 2 experiments using a minimum of 6 mice per group.
Values are the mean6SEM. P values were determined by two-way
analysis of variance (A) or Wilcoxon’s signed rank test (C and D).
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In light of these results and our previous work
that demonstrated an association between genotype at
rs12212067 and the radiographic course of RA, we elected
to examine other indices of disease severity in a large
prospectively collected cohort of early RA patients.
First, we considered other radiographic measures, as it
has recently been suggested that the number of eroded
joints may constitute a more accurate measure of joint
damage (26). We confirmed that irrespective of the mea-
sure used, carriage of the minor allele at rs12212067 was
associated with lower radiographic damage over time
(i.e., lower Larsen score, lower modified Larsen score,
and fewer erosions) (Table 1). In other words, patients
with a milder disease course were more likely to carry the
rs12212067 minor allele than those with a more severe
disease course (the average minor allele frequency of
rs12212067 in NOAR is 9.6%). The effect of FOXO3A
rs12212067 on the Larsen score remained significant after
adjustment for treatment (effect size equal to a reduction
of 1.50 Larsen units for carriage of the G allele; P5 0.009)
and was independent of the SE in a bivariate analysis
(P5 0.002) (Table 1). However, although this association
was significant, the proportion of the variance of the
Larsen score explained by the carriage of rs12212067 was
low (0.07%).
Given these data and the TGFb1-driven inflam-
matory pathway that FOXO3 has been shown to regu-
late (10), we postulated that the effect of FOXO3A on
radiographic outcome might be mediated by a reduction
of inflammation and not by a direct effect on the bone,
as has been suggested for other genetic markers of RA
severity (5). We therefore examined the entire NOAR
cohort to determine whether there was an association
between rs12212067 genotype and nonradiographic
measures of inflammation, disease activity, or outcome
(including the CRP level, swollen joint count, tender
joint count, the HAQ score, and DAS28). Data avail-
ability and the frequency and duration of follow-up for
these different measures varied and are shown in Sup-
plementary Table 2 (available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.39760/abstract).
We observed significant associations of rs12212067
genotype with the DAS28, swollen joint count, and CRP
level and a nominally significant association with the
HAQ score (P5 0.013, although the stringent bootstrap
correction for interindividual correlation meant that the
corrected P value was 0.11). Notably, there was also a con-
sistent direction of effect across all of the variables, with
minor allele carriage at rs12212067 generally associating
with indices of milder disease, and with effect sizes that
were of a comparable magnitude to those that were associ-
ated with the SE (Tables 1 and 2). However, the propor-
tion of the phenotype variance explained by the carriage of
rs12212067 remained low for nonradiographic measures of
Table 1. Association of FOXO3A and the shared epitope with radiologic measures of disease out-
come in patients with rheumatoid arthritis*
Shared epitope FOXO3A (rs12212067)
Effect size (95% CI) P Effect size (95% CI) P
Larsen score
Unadjusted 1.42 (0.50, 2.34) 0.0013 21.50 (22.73, 20.26) 0.0089
Adjusted for the shared epitope – – 21.88 (23.15, 20.60) 0.0020
Adjusted for treatment – – 21.50 (22.75, 20.25) 0.0094
Modified Larsen score 1.51 (0.66, 2.35) 0.00024 21.65 (22.80, 20.50) 0.0025
No. of eroded joints 0.36 (0.17, 0.54) 0.00012 20.29 (20.53, 20.06) 0.0073
* Effect size represents the change in Larsen score units or in the number of eroded joints. The modified
Larsen score was obtained by recalculating the Larsen score using the presence of joint space narrowing
(in the absence of any other modification) as 0 instead of 1, in order to reduce potential misclassification
due to osteoarthritis. 95% CI5 95% confidence interval.
Table 2. Association of FOXO3A and the shared epitope with non-
radiologic measures of disease outcome or activity in patients with inflam-
matory arthritis*





HAQ score 1.15 (1.06–1.25) 0.00019 0.94 (0.84–0.96) 0.11
DAS28 1.19 (1.02–1.38) 0.013 0.78 (0.66–0.93) 0.0029
SJC 1.22 (1.05–1.42) 0.0052 0.86 (0.73–1.03) 0.048
TJC 1.08 (0.80–1.45) 0.3 0.84 (0.59–1.20) 0.17
CRP 1.38 (1.09–1.72) 0.0032 0.74 (0.56–0.97) 0.016
* For outcome measures modeled with quantile regression, the values are
the odds ratio (raised to the power of the observed coefficient), normal-
based 95% confidence interval (95% CI), and P value by 1-tailed boot-
strap method. For C-reactive protein (CRP) modeled with zero-inflated
negative binomial regression, the results from the categorical (inflate)
part of the model are reported: odds ratio (raised to the power of the
observed coefficient for being non-zero), 95% CI, and robust P value.
HAQ5Health Assessment Questionnaire; DAS 285Disease Activity
Score in 28 joints; SJC5 swollen joint count; TJC5 tender joint count.
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disease outcome (the proportion of the variance of DAS28
explained by only the SNP was 0.09%).
The anti–cyclic citrullinated peptide (anti-CCP)
antibody status is a strong and well-established predictor
of disease severity (27), and the effect of the SE on RA
severity is mainly mediated by anti-CCP (23,28). In order
to investigate the influence of anti-CCP status on the
association of FOXO3A rs12212067, we adjusted the
effect of rs12212067 for anti-CCP status and performed
a stratification analysis by anti-CCP status (Table 3).
Although the effect of the SE on disease severity and
activity disappeared completely after adjustment or strat-
ification, the effect of rs12212067 on the Larsen score or
DAS28 remained significant irrespective of anti-CCP sta-
tus (the effect size adjusted for anti-CCP was equal to a
reduction of 1.26 Larsen units for carriage of the G allele
(95% confidence interval 22.49, 20.03; P5 0.023), and
the odds ratio for the DAS28 was 0.78 (95% confidence
interval 0.67, 0.90; P5 4.33 1024).
DISCUSSION
FOXO3 is a transcription factor that has been
linked to the regulation of immune responses through
the use of systems biology (29) and knockout mouse
models (30), and it has been shown to be overexpressed
in blood and synovial leukocytes in RA (31). We have
previously reported that minor allele carriage at
rs12212067, a noncoding SNP in FOXO3, is associated
with a milder course of several TNF-driven diseases, in-
cluding RA, and we have described a FOXO3-dependent
pathway that is regulated by this genetic variant and
which modulates inflammatory responses in monocytes
via TGFb1 induction (10). This genetic association,
however, was not detected in a follow-up study by van
Steenbergen and colleagues (13), which included 5
smaller RA cohorts and a mixture of prospective and ret-
rospective patients as well as early and established RA. A
nonsignificant trend toward a protective effect of the
minor allele at rs12212067, which is consistent with our
results, was observed in their meta-analysis, however,
particularly in the cohorts of early RA patients for whom
multiple sets of radiographs were available (13). None-
theless, given these apparently contradictory reports
(10,13), we sought to better understand what role, if any,
FOXO3 plays in influencing disease course in RA.
We first sought to establish whether a contribu-
tion of FOXO3 to the course of immune-mediated
arthritis was biologically plausible, given that genetic
associations alone do not establish biologic relevance to
disease. Indeed, even though we had previously identi-
fied an inflammatory pathway that is modulated by
genetic variation at rs12212067, this does not definitively
prove that any association with radiographic outcome in
RA is due to effects on inflammation. We therefore
examined the role of Foxo3 in immune-mediated arthri-
tis in vivo in an animal model that has previously been
extensively and successfully used to delineate patho-
genic mechanisms in RA and to test new therapies (18).
Based on the results of these experiments, we then used
detailed phenotype data from the largest cohort of early
RA patients worldwide to assess associations with other
measures of inflammation and disease severity.
We demonstrated that altered Foxo3 function
does modulate the severity of autoimmune arthritis in
vivo, and we identified genetic associations with several
Table 3. Adjustment for, and stratification by, anti-CCP status*
Anti-CCP positive Anti-CCP negative
Adjusted for
anti-CCP status
Effect size (95% CI) P Effect size (95% CI) P Effect size (95% CI) P
Shared epitope
Larsen score 1.05 (21.45, 3.54) 0.205 0.23 (20.61, 1.07) 0.295 0.16 (20.80, 1.11) 0.373
DAS28 1.13 (0.85, 1.50) 0.205 1.08 (0.90, 1.28) 0.206 1.10 (0.95, 1.27) 0.104
FOXO3A (rs12212067)
Larsen score 21.82 (24.90, 1.26) 0.123 20.98 (21.96, 0.01) 0.026 21.26 (22.49, 20.03) 0.023
DAS28 0.78 (0.60, 1.02) 0.033 0.80 (0.66, 0.96) 0.010 0.78 (0.67, 0.90) 4.3 3 1024
* The association studies presented in Table 1 for the Larsen score in rheumatoid arthritis patients and in Table 2 for the Disease Activity Score
in 28 joints (DAS28) in inflammatory polyarthritis patients were again performed either by adjusting for the anti–cyclic citrullinated peptide
(anti-CCP) status; that is, the analysis was restricted to anti-CCP–positive disease or anti-CCP–negative disease. Since the effect of the shared
epitope is almost completely mediated by anti-CCP, it disappears completely. However, the adjustment has no major influence on the association
of FOXO3A rs12212067. Stratification decreases the sample size and therefore the power, which is likely to explain the lack of significance for
the Larsen score in the smaller anti-CCP–positive group. Overall, these results indicate that the biologic pathways that mediate the effect of the
shared epitope and FOXO3A are different. P values are 1-tailed. See Tables 1 and 2 for explanations of dimensions and interpretation of effect
sizes. 95% CI5 95% confidence interval.
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other indices of inflammation and disease severity in
RA patients. Together, these results strengthen the pre-
viously reported association of FOXO3 with outcome in
RA. Moreover, these data suggest that rather than hav-
ing a direct effect on bone, the contribution of FOXO3
to outcome in RA is likely to be by modulating inflam-
mation (e.g., the CRP level) and disease activity (e.g.,
swollen joint count, DAS28), which would then lead to
differences in radiographic outcome (e.g., Larsen score,
erosions).
However, the effect of FOXO3 is independent of
the SE and of the presence of anti-CCP antibodies, which
is consistent with 2 different mechanisms of action for
these 2 different genetic markers. Importantly, the size of
the effects on radiographic damage and the DAS28, while
statistically significant, are unlikely to be clinically useful in
isolation (e.g., for applications such as predicting disease
outcome), as the proportion of the phenotype variance
explained by the FOXO3 SNP alone is ,0.1% (0.07% for
the Larsen score and 0.09% for the DAS28).
This does not, however, preclude the inclusion of
this SNP in a model that could incorporate several predic-
tive factors (e.g. genetic, demographic, clinical, and envi-
ronmental). In the future, such a model could comprise a
set of several hundreds of SNPs of small effect sizes. With
current technological advances and the commercialization
of high-throughput (chip-based) genotyping platforms for
clinical applications, this approach will become a realistic
diagnostic/prognostic option. Moreover, irrespective of the
utility of this SNP for predicting disease course, by study-
ing the functional effects of such associations, it may be
possible to uncover previously unappreciated pathways
that are amenable to pharmacologic intervention and so
develop better treatments.
Such a discrepancy between the effect size of an
associated SNP and the therapeutic potential of target-
ing the underlying biology has already been observed
in cardiovascular medicine, where genetic variants in
HMGCR are associated with very modest changes in
serum levels of low-density lipoprotein (;5% [32]), but
the protein product of this gene, hydroxymethylglutaryl-
coenzyme A reductase, is the pharmacologic target of the
most effective drug treatment for hypercholesterolemia
(statins) (33). An important caveat, however, is that the
associations of rs12212067 with the indices of RA severity
described herein have not yet been replicated, even
though these indices were selected because of the a priori
hypothesis that minor allele carriage at rs12212067 would
be associated with milder disease. Accordingly, these
associations should be examined further in larger and
appropriately powered replication cohorts.
Since the advent of GWAS, it has been common-
place for the reporting of new genetic associations to be
followed by several smaller, often underpowered, studies
that attempt to replicate the reported associations, with
varying degrees of success. In the present study, we
confirmed that FOXO3 plays an important role in
determining the course of immune-mediated arthritis
in vivo, and we detected associations between genotype
at rs12212067 and a range of RA severity measures. It
is therefore important to consider why this association
was not detected in a previous follow-up study (13).
One possibility is that the genetics and biology of
disease outcome are genuinely different between the
populations studied. However, given that both study
populations were derived from the same ethnic ances-
try, this seems less likely, and other possibilities need
to be considered.
An alternative explanation is that the relatively
small size of the individual cohorts in the replication study
(13) may have limited their power to detect any effect.
This is likely to have been further hampered by the
considerable intercohort heterogeneity, both in terms of
clinical phenotype (i.e., early versus established RA) and
in terms of the available radiographic data. For example,
in 50% of the cases, only a single set of radiographs
were available. This meant that progression could not be
assessed in a uniform way across all cohorts, being
directly measured in some and extrapolated based on
assumed linear disease progression in others, an assump-
tion that is unlikely to be valid for most patients (34).
Standardized phenotype definitions are critical for multi-
center studies in order to prevent the introduction of site-
based bias(es) and to ensure that the final meta-analysis
is interpretable (35). Accordingly, we would contend that
rather than disproving a role of FOXO3 in the outcome of
RA, this negative study actually reemphasizes the need
for consistent definitions in replication studies, as has
been highlighted by others (35).
Collectively, therefore, our data provide further sup-
port for the observation that an SNP which has not been
associated with susceptibility to RA (minor allele frequency
of 0.103 in 3,879 UK RA cases and 0.104 in 8,428 UK
controls, with an odds ratio of 0.994 [95% confidence inter-
val 0.910, 1.085); P5 0.89 [2]) is associated with disease
outcome. This highlights possible new directions for candi-
date gene or pathway-based studies in complex disease
genetics and suggests that by identifying other genetic
variants that associate with outcome, it may ultimately be
possible to develop prognostic tests that have sufficient
performance to guide treatment decisions. As with studies
of disease susceptibility, however, such work will probably
require large sample sizes and meta-analyses to confirm
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associations at genome-wide significance levels. Interna-
tional consortia will undoubtedly be critical in achieving
this goal.
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